Colombia Organ Transplant Immunosuppressant Drugs Market – Industry Trends and Forecast to 2030

Colombia Organ Transplant Immunosuppressant Drugs Market, By Organ Type (Kidney, Liver, Heart, Lung, Pancreas, Others), Drug Class (Calcineurin Inhibitors, Antimetabolite Immunosuppressants, Steroids, M0TOR Inhibitor, Monoclonal Antibody, Others), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End User (Hospitals, Transplant Centers), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Colombia Organ Transplant Immunosuppressant Drugs Market Analysis and Size

The organ transplant immunosuppressant drugs market is projected to witness significant growth during the forecast period. Increasing demand for novel tissue transplantation products and organ transplantation used for the treatment of organ failure is a major factor which leads to the market growth. Unhealthy dietary habits, alcohol consumption, lack of exercise, and drug abuse are some of the important causes of organ failure. It has been observed that tissue products were the highest revenue-generating segment in 2022, having a market share of 57.8%.

Data Bridge Market Research analyses a growth rate in the organ transplant immunosuppressant drugs market in the forecast period 2023-2030. The expected CAGR of organ transplant immunosuppressant drugs market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 0.18 billion in 2022, and it would grow upto USD 0.24 billion by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Colombia Organ Transplant Immunosuppressant Drugs Market Scope and Segmentation

Market Definition

Organ transplant immunosuppressant drugs are used in organ transplant to avoid reverse acute rejection and organ rejection, decrease the destruction of affected tissues in autoimmune and inflammatory diseases and for the treatment of graft versus host disease during organ transplantation The rise in the incidence of end-stage renal disease (ESRD) demands the higher usage of organ transplant immunosuppressant drugs.

Colombia Organ Transplant Immunosuppressant Drugs Market Dynamics

Drivers

• Increasing Demand for Organ Transplant

The rise in the organ transplant demand can be credited to an increase in the incidence of acute diseases, which in turn leads to an increase in organ failures. For instance, diabetes and high blood pressure are considered to be the most common causes of end-stage renal disease, in which kidney transplants or dialysis are the only treatment options to keep a patient alive. According to the records of the U.S. Department of Health & Human Services, around 122,913 patients in the U.S. were waiting to receive organs for transplant in 2019. Thus, the demand for advanced transplantation products for the treatment of organ failure is high. This boosts the market growth.

• Technological Advancements

Numerous technological advancements in this sector are projected to increase the growth of the market. For instance, in September 2015, Arthrex Inc. launched ArthroFlex Acellular Dermal Matrix, a new orthobiologic product proposed for use in capsular reconstruction. This product allows preservation of its growth factors and native collagen scaffold and elastin and permits transplant to be successfully incorporated into the recipient.

Opportunities

• Higher Mergers and Acquisitions

Numerous manufacturers are aiming on new product development, mergers & acquisition, and collaborations to increase their current product portfolio and maintain their constant position in the market. For instance, in September 2016, Stryker Corporation announced the acquisition of Instratek. It is a top manufacturer of numerous minimally invasive soft tissue recession instruments for ankle, foot, and upper extremity procedures.

• Growing Sales of Immunosuppressive Drugs

Tissue products for transplantation accounted for the largest share in 2021, and this category is expected to maintain its position in the upcoming future because of the growing use of orthobiologics in orthopedic procedures for normal functioning restoration, tissue healing, and pain minimization, along with the increasing elderly population globally. Additionally, start-up companies in this field are receiving investments to enlarge their business. Thus, this factor is creating much opportunities for the market growth.

Restraints/Challenges

• High Cost

The huge cost associated with organ transplantation and several other immunosuppressive drugs restrain the market growth. Patients who cannot afford these transplantation procedures undergo very late recovery and thus it leads to the restriction of the market.

• Unavailability of Treatment

Not all the treatments are accessible in all countries, limiting market growth. There are several underdeveloped countries in which the modified treatments are not available.  Thus, it restricts the growth of the market.

This organ transplant immunosuppressant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the organ transplant immunosuppressant drugs market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Colombia Organ Transplant Immunosuppressant Drugs Market       

There has been a significant proportion of COVID-19 patients who were hospitalized in medical centers and were bound to restrict to these patients. The pandemic caused a drop in organ transplant surgery enrolment worldwide.

The decrease in the number of transplantation and organ donation procedures is majorly because of factors such as engaged surgeons, lockdown, unavailability of resources, and travel restrictions. Patients tested positive for COVID-19 were restricted from donating organs due to the possibility of infection. Moreover, another major concern prompting transplantation operations was the possibility of immunosuppressant drug interactions with COVID-19 therapy agents, that had led to a substantial number of organ failures from graft donors.  

Recent Development:

• In November 2020, Lupin announced the launch of the generic immunosuppressant drug called as Tacrolimus, in the U.S. market that is particularly indicated for prophylaxis of organ rejection in the allogeneic liver, kidney, and heart transplant.

Colombia Organ Transplant Immunosuppressant Drugs Market Scope

The organ transplant immunosuppressant drugs market is segmented on the basis of organ type, drug type, drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Organ Type

• Kidney
• Liver
• Pancreas
• Heart
• Lung
• Small Bowel
• Kidney/Pancreas
• Others

Drug Class

• Calcineurin Inhibitors
• Antimetabolite Immunosuppressants
• Steroids
• M0TOR Inhibitor
• Monoclonal Antibody
• Others

Drug Type

• Generics
• Branded

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Transplant Centers

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Competitive Landscape and Organ Transplant Immunosuppressant Drugs Market Share Analysis

The organ transplant immunosuppressant drugs market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to organ transplant immunosuppressant drugs market.

Key players operating in the organ transplant immunosuppressant drugs market  include:

• Teva Pharmaceutical Industries Ltd (Israel)
• Mylan N.V (U.S.)
• Johnsons & Johnsons Services Inc (U.S.)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Aurobindo Pharma (India)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc (U.K.)
• Pfizer Inc.(U.S.), Astellas Pharma Inc.(Japan)
• Sanofi (France)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Alkem Labs Ltd (India)
• Abbott (U.S.)